Si	Substitute for form 1449APTO INFORMATION D. CLOSURE		COMPOSITE IF KNOWN		
	INFORMATION D. LOSURE		Application Number	10/531504	
		37 A T	DI ICANIT	Filing Date	March 11, 2005
3	STATEMENT BY APPLICANT		First Named Inventor	John J. Renger et al	
			,	Group Art Unit	
	(use as many sheets as necessary)		Examiner Name		
Sheet	1	of	2	Attorney Docket Number	21245YP

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document	Kind Code known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
					133/04/6344 BC
·					
			· .		
			<u> </u>	·	
			-		
			<u> </u>		
	<u>.</u>		ļ		
				·	

			FOREIGN PA	TENT	DOCUMENTS	
Examiner Initials*	Cite No.		mber	Kind Code (known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
7S.J./		WO 93/04047			Merck & Co., Inc.	03/04/1993
/S.J./		WO 01/02561			Neuromed Technologies, Inc.	01/11/2001
				<u> </u>		
				ļ	- W	
				<u> </u>		
Examine Signatur	er re	/Sahar	Javanmard/		Date Considered	12/03/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form * IDS Form* (IDS Folder), Merck & Co., Inc., 09/05/2003)

JC13 Rec'd PCT/PTO 13 AFK 2UU3

SUBSTITUTE for PTO/SB/08A (08-03), Information Disclosure Statement by Applicant Patient and Trademark Office; U.S DEPARTMENT OF COMMERCE

		litute for form 1449B/PTO			COMPANY OF LF KNOWN		
	INFORMATION D. LOSURE			Application Number	10/531504		
				Filing Date	March 11, 2005		
}	STATEMENT BY APPLICANT		First Named Inventor	John J. Renger et al			
			Group Art Unit				
	(use as many sheets	s as r	iecessary)	Examiner Name			
Sheet	2	of	2	Attorney Docket Number	21245YP		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.			
/S.J.	1	Santi, C. et al. Differential Inhibition of T-Type Calcium Channels by Neuroleptics. <u>Journal Neuroscience</u> . 15 January 2002, vol. 22, No. 2, pages 396-403.			
/S.J./		Massie, B.M. Mibefradil a T-Type Channel-Selective Calcium Antagonist: Clinical Trails in Chronic Stable Angina Pectoris. American Jouranl of Hypertension. April 1998, vol 11, No. 4, pages 95S-102S.			
	-				
	:				
		,			
		·			

Examiner Signature	/Sahar Javanmard/	Date Considered	12/03/2007

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form* IDS Form* (IDS Folder), Merck & Co., Inc., 09/05/2003